
Lirafugratinib + LITESPARK011
OncoPharm
00:00
Combination Therapy Has Greater Treatment Toxicity
John Bazar explains that more patients discontinued lenvatinib or belzutifan for toxicity and describes cardiac failure and left-ventricular-function safety signals.
Play episode from 11:41
Transcript


